Stem Cell Transplant for Blood Cancers
(AB-CliniMACs Trial)
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the idea that Stem Cell Transplant for Blood Cancers is an effective treatment?
The available research shows that Stem Cell Transplant for Blood Cancers is an effective treatment because it has a strong anti-tumor effect, known as 'graft versus leukemia', which helps fight blood cancers. Studies indicate that this treatment is a proven option for patients with blood-related cancers, offering a curative potential. Although there are risks like graft versus host disease, the treatment is expanding due to its demonstrated effectiveness in both myeloid and lymphoid cancers. Compared to other treatments, it provides a unique immune response that targets cancer cells, making it a powerful option for patients with high-risk blood cancers.12345
What data supports the effectiveness of the treatment Allogeneic Stem Cell Transplant for blood cancers?
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a proven treatment for blood cancers, as it uses the immune system from a donor to fight cancer cells, known as the 'graft versus leukemia' effect. This treatment has shown benefits in both myeloid and lymphoid blood cancers, despite some risks like graft versus host disease, which occurs when the donor's immune cells attack the patient's body.12345
What safety data is available for stem cell transplants in blood cancer treatment?
Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with significant risks, including morbidity and mortality. While the donation process is generally safe, with the main risk being related to anesthesia, the transplantation itself can lead to serious adverse events, including cardiac issues and late-onset pulmonary complications. Long-term survivors are at risk for cardiovascular disease, and there is limited data on the long-term effects on cardiac function. Despite these risks, HSCT remains a potential cure for various diseases, but careful monitoring and further studies are needed to better understand and mitigate these risks.678910
Is allogeneic stem cell transplantation safe for humans?
Allogeneic stem cell transplantation can be risky, with potential for serious side effects like heart problems and lung issues, especially in long-term survivors. However, the donation process itself is generally safe, with the main risks being related to anesthesia and some pain at the donation site.678910
Is the treatment Allogeneic Stem Cell Transplant a promising treatment for blood cancers?
Yes, Allogeneic Stem Cell Transplant is a promising treatment for blood cancers. It can cure patients by using the body's immune system to fight cancer cells, known as the 'graft versus leukemia' effect. This treatment has shown success in both myeloid and lymphoid cancers, and new methods have made it safer and more effective. It also offers hope for other types of cancers, like colorectal cancer, by using the body's immune response.14111213
How is the treatment Allogeneic Stem Cell Transplant different from other treatments for blood cancers?
Allogeneic Stem Cell Transplant is unique because it uses stem cells from a donor to help the patient's body fight cancer through a process called graft-versus-leukemia, where the donor's immune cells attack the cancer cells. This treatment can be curative and is often used when other treatments have failed, but it carries risks like graft-versus-host disease, where the donor cells attack the patient's healthy tissues.14111213
What is the purpose of this trial?
This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and graft versus host disease (GVHD), and one year leukemia free survival.
Research Team
Timothy S Olson, MD, PhD
Principal Investigator
Children's Hospital of Philadelphia
Eligibility Criteria
This trial is for patients with various blood cancers like leukemia and lymphoma who are in remission or have minimal disease presence. They must have acceptable organ function, no active untreated infections, and a negative pregnancy test if applicable. Those who've had previous allogeneic transplants or lack a suitable donor can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive α/β T cell-depleted peripheral Stem Cell Transplantation with various conditioning regimens including TBI, Busulfan, Thiotepa, and Cyclophosphamide
Follow-up
Participants are monitored for engraftment, graft versus host disease (GVHD), and leukemia-free survival
Treatment Details
Interventions
- Allogeneic Stem Cell Transplant
- Alpha Beta T cell depletion
Allogeneic Stem Cell Transplant is already approved in United States, European Union for the following indications:
- Acute Leukemia
- Chronic Leukemia
- Lymphoma
- Multiple Myeloma
- Other hematologic malignancies
- Acute Leukemia
- Chronic Leukemia
- Lymphoma
- Multiple Myeloma
- Other hematologic malignancies
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital of Philadelphia
Lead Sponsor